Commercial vehicle maker Ashok Leyland's total sales in December declined 19%YoY to 7,299 units amid continued sluggish demand for medium and heavy trucks. Sales of its small truck Dost accelerated 88%to 2,069 units,last ...
Tags: Ashok Leyland, Sales, Commercial vehicle
bioMérieux has recently launched the new CE-marked VIDAS® Anti-HCV test for the detection of antibodies to the hepatitis C virus (HCV), extending the Company’s current product range to provide a complete test menu for ...
Tags: Anti HCV Test, Viral Hepatitis, immunoassay platform, fluorescent assay
The adverse side effects of some medications for hepatitis C can now be observed and studied in laboratory conditions, using petri dishes and test tubes, thanks to the development of a new method by US researchers. A team led by Craig ...
Tags: anti-HCV treatments, hepatitis, disease, PLOS Pathogens
Business Line reported that TATA Motors’ posted a 13.43% fall in total sales, including exports, at 66,500 vehicles for November 2012, compared with 76,823 units sold during the same month a year ago. The company in a statement ...
Tags: Tata motors, fall in sales, sales of commercial vehicles
The US Food and Drug Administration (FDA) has granted fast track designation for Idenix Pharmaceuticals' IDX719 to treat chronic hepatitis C infection (HCV). IDX719 is an NS5A inhibitor that demonstrated pan-genotypic activity in a recent ...
Tags: IDX719, HCV, chronic hepatitis C infection
Tata Motors has reported 15% increase in sales (including exports) of commercial and passenger vehicles to 73,491 vehicles during July 2012 compared to same period in 2011. Domestic sales of the company's commercial and passenger vehicles ...
Tags: Tata, sales up, passenger vehicles
Tata Motors has reported 4% increase in sales (including exports) of commercial and passenger vehicles to 64,347 vehicles during May 2012 compared to same period in 2011. Domestic sales of the company's commercial and passenger vehicles ...
Tags: Tata, sales up, passenger vehicles
The FDA has granted fast track designation for Achillion Pharmaceuticals' ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV). ACH-3102 is a pan-genotypic second-generation NS5A inhibitor ...
Tags: FDA Fast Track Designation, chronic hepatitis C, pharmaceutical product